Calderón-Moore A, Pizarro-Castellanos M, Rizzoli-Córdoba A

Language: Spanish
References: 15
Page: 265-270
PDF size: 94.43 Kb.

ABSTRACT

Background. Available information on clinical guidelines and review articles is controversial and is insufficient to determine the clinical efficacy of supplementation with omega 3 and omega 6 fatty acids in neurodevelopmental disorders. Additional treatment may be effective for the treatment of these disorders.
Methods. We conducted a systematic review based on the guidelines of the Cochrane group by searching for clinical trials in MEDLINE, COCHRANE DATA-BASE in the time interval 1990 to 2011, in English and Spanish, and in pediatric patients that comply with the information required by the CONSORT group. One hundred and two articles were obtained; 97 articles were excluded choosing five randomized, double-blind, placebo-controlled trials to perform the review.
Results. In the trials analyzed we found no significant difference in the improvement of ADHD symptoms between placebo group and the intervention, but there was clear clinical improvement. No serious adverse events were reported. There are no similar characteristics in the reviewed articles to carry out a meta-analysis and accurate assessment of the effectiveness of supplementation.
Conclusions. With the results of this systematic review, we cannot state categorically that the use of this supplementation is significantly effective due to the different characteristics of the studies described above. However, due to clinical improvement and adequate safety profile, it may be useful without replacing pharmacological treatment.

REFERENCES

1. López-Ibor AJ, Valdés MM, Flores I FT. DSM-IV-TR. Manual Diagnóstico y Estadístico de los Trastornos Mentales. Barcelona: Masson Elsevier; 2003. Disponible en: http://148.228.156.172/DSMIV/DSMIV/CREDITOS.PDF

2. Floet AM, Scheiner C, Grossman L. Attention-deficit/hyperactivity disorder. Pediatr Rev 2010;31:56-69.

3. Richardson AJ, Montgomery P. The Oxford-Durham Study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005;115:1360-1366.

4. Das UN. Long-chain polyunsaturated fatty acids in the growth and development of the brain and memory. Nutrition 2003;19:62-65.

5. Colquhoun I, Bunday S. A lack of essential fatty acids as a possible cause of hyperactivity in children. Med Hypothesis 1981;7:673-679.

6. Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, Lipp SR, et al. Essential fatty acid metabolism in boys with attetiondeficit hyperactivity disorder. Am J Clin Nutr 1995;62:761-768.

7. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 2007;28:82-91.

8. Milte CM, Sinn N, Buckley JD, Coates AM, Young RM, Howe PR. Polyunsaturated fatty acids, cognition and literacy in children with ADHD with and without learning difficulties. J Child Health Care. 2011;15:299-311.

9. Huss M, Völp A, Stauss-Grabo M. Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems–an observational cohort study. Lipids Health Dis 2010;9:105.

10. Aben A, Danckaerts M. Omega-3 and omega-6 fatty acids in the treatment of children and adolescents with ADHD. Tijdschr Psychiatr 2010;52:89-97.

11. Davey J, Turner RM, Clarke MJ, Higgins JP. Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews: a cross-sectional, descriptive analysis. BMC Med Res Methodol 2011;11:160. doi:10.1186/1471-2288-11-160.

12. Schulz K, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010;7:e1000251. doi:10.1371/journal.pmed.1000251.

13. Johnson M, Ostlund S, Fransson G, Kadesjo B, Gillberg C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 2009;12:394-401.

14. Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid–containing food administration on symptoms of attention-deficit/hyperactivity-disorder—a placebo-controlled double-blind study. Eur J Clin Nutr 2004;58:467-473.

15. Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berreta MC, Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexanoic acid supplementation in children with attetion-deficit/hyperactivity disorder. J Pediatr 2001;139:189-196.